WEBULL
WebtradeDownload

HOYA (TSE:7741) Stock Keeps Margin Strength In Focus After Profit Jump

Simply Wall St · 2d ago

HOYA entered this earnings day with a premium story and a tired share price. The stock had slipped roughly 11% over the past three months even as investors paid about 30.9x trailing earnings. The quarter itself pushed back on that fatigue. Revenue reached ¥255,742m and basic EPS came in at ¥196.61, keeping the profit engine in focus for a company already running at a net margin of 27.2% over the past year.

For a market that has started to question the valuation, this set of numbers keeps the margin story at the center of the HOYA debate.

Love HOYA's rich margins but uneasy about paying a premium P/E for a stock that has slipped recently? Check out the 58 resilient stocks with low risk scores for ideas that combine resilient balance sheets with more measured valuation risk.

Q1 2027 Earnings Summary

  • Revenue, Q1 2027 vs. Q1 2026: ¥255,742m vs. ¥220,882m (up 15.8%)
  • Net Income, Q1 2027 vs. Q1 2026: ¥65,791m vs. ¥51,840m (up 26.9%)
  • Basic EPS, Q1 2027 vs. Q1 2026: ¥196.61 vs. ¥151.24 (up 30.0%)
  • Net Profit Margin, Trailing 12 Months vs. Prior Year: 27.2% vs. 23.6% (reflecting a higher margin profile over the last year)

Prefer clean charts over scrolling through pages of numbers on HOYA? View HOYA's full visual financial picture, including a clear look at its profitability trends, in the interactive company report for HOYA..

TSE:7741 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TSE:7741 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Stronger Margins Keep HOYA’s Balanced Story Intact

For investors leaning positive on HOYA, this quarter lines up with the idea of a balanced healthcare and semiconductor supplier. Revenue of ¥255,742m and higher basic EPS alongside a trailing net margin of 27.2% support the view that both Life Care and tech aligned products are contributing to a more profitable mix. Recent FDA clearance for new PENTAX Medical endoscopes also fits the healthcare stability angle. Taken together, these signals keep the diversified, quality focused narrative broadly in step with the financial trajectory.

Share Price Drift Leaves Room For Bearish Questions

Bears will point out that HOYA’s 90 day share price decline of about 11% and 30 day decline of about 4% show the market has not fully embraced this earnings strength. The earlier slide in the stock despite rising revenue and EPS suggests concerns about cyclicality in the Information & Communications side or sustainability of margins have not disappeared. However, the 7 day gain of roughly 0.5% hints that immediate fears may be easing slightly after the report rather than intensifying.

With HOYA trading on a premium 30.9x P/E, even small shifts in cash generation or leverage could significantly affect its future flexibility. Check the full liquidity, debt and cash runway picture in the financial health analysis of HOYA stock.

Stay Ahead With HOYA And Simply Wall St

If HOYA's rich margins and recent earnings have your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on how the share price lines up with its fair value and spot a price that fits your plan. After you decide to take a position, keep your focus on what matters by managing your holdings through the Portfolio Command Center that highlights key developments and filters out day to day noise. For a broader view on HOYA and similar stocks, draw on the shared experience of other investors through the Community and see how different theses stack up. This combination helps you surface potential catalysts and risks early so you can move faster and stay ahead of the market.

Seeking Alternatives Beyond HOYA Right Now

Fresh stock ideas can move from under the radar to flying fast once momentum starts. Scan these curated lists before the crowd catches up and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.